Table 2.
Treatment of COVID-19 by Group
| Variable | Full Cohort | P Value | Propensity Score–Matched Cohort | P Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative SARS-CoV-2 RT-PCR (n = 66) |
Positive SARS-CoV-2 RT-PCR (n = 188) |
Negative SARS-CoV-2 RT-PCR (n = 66) |
Positive SARS-CoV-2 RT-PCR (n = 132) |
|||||||
| No. | % a | No. | % a | No. | % a | No. | % a | |||
| Hydroxychloroquine | 34 | 51.5 | 158 | 84.0 | <.001 b | 34 | 51.5 | 112 | 84.8 | <.001 b |
| Treatment duration, median d (IQR) | 2.5 | 1–5 | 7.0 | 4–10 | <.001 c | 2.5 | 1–5 | 7.0 | 4–10 | <.001 c |
| Azithromycin | 56 | 84.8 | 162 | 86.2 | .791 b | 56 | 84.8 | 117 | 88.6 | .449 b |
| Treatment duration, median d (IQR) | 4.0 | 2–6 | 6.0 | 4–9 | <.001 c | 4.0 | 2–6 | 6.0 | 4–10 | <.001 c |
| Associated and isolated use | ||||||||||
| Hydroxychloroquine + Azithromycin | 27 | 42.9 | 135 | 73.0 | 27 | 42.9 | 98 | 74.8 | ||
| Azithromycin | 29 | 46.0 | 27 | 14.6 | <.001 b | 29 | 46.0 | 19 | 14.5 | <.001 b |
| Hydroxychloroquine | 7 | 11.1 | 23 | 12.4 | 7 | 11.1 | 14 | 10.7 | ||
| Lopinavir/Ritonavir | 3 | 4.5 | 22 | 11.7 | .093 b | 3 | 4.5 | 12 | 9.1 | .255 b |
| Treatment duration, median d (IQR) | 1.0 | 1–1 | 6.5 | 5–9 | .008 c | 1.0 | 1–1 | 8.0 | 5.5–9.5 | .009 c |
| Tocilizumab | 0 | 0.0 | 14 | 7.4 | .024 d | 0 | 0.0 | 10 | 7.6 | .022 d |
| Treatment duration, median d (IQR) | … | … | 1.0 | 1–2 | … | … | … | 1.0 | 1–1 | … |
Note. SARS-CoV-2, severe acute respiratory coronavirus virus 2; RT-PCR, reverse transcriptase-polymerase chain reaction; IQR, interquartile range.
a
Percentage unless otherwise specified.
b
Data presented as no. and %, compared using the χ2 test.
c
Data presented as median and interquartile range, compared using the Mann-Whitney U test.
d
Data presented as no. and % compared using the Fisher exact test.